

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, the United States or in any other jurisdictions where such offer pursuant to legislation and regulations in such relevant jurisdictions would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled "Important notice" at the end of this announcement and in the tender offer document which will be published shortly before the beginning of the acceptance period for the Offer.

Magle Chemoswed Holding AB publishes offer document and announces updated timetable regarding the cash offer to the shareholders of Amniotics AB

On 22 March 2024, Magle Chemoswed Holding AB ("Magle Group") announced a recommended public offer to the shareholders of Amniotics AB ("Amniotics") to tender all their shares to Magle Group for SEK 0.004 in cash per share (the "Offer"). Today, 5 April 2024, Magle Group publishes the offer document regarding the Offer.

The offer document is available on Magle Group's website (www.maglegroup.com) and on Vator Securities' website (www.vatorsecurities.se)

The acceptance form for the shares in the Offering is available on Magle Group's website and on Vator Securities' website. A pre-printed acceptance form will be sent to shareholders in Amniotics whose shares were directly registered with Euroclear Sweden AB on 5 April 2024, except to shareholders domiciled in jurisdictions that are excluded (see above).

The acceptance period for the Offer begins on 8 April 2024 and ends on 3 May 2024. The outcome of the Offer will be announced through a press release on or about 7 May 2024.

Settlement is expected to commence on or around 13 May 2024. Settlement will commence as soon as Magle Group has announced that the conditions for the Offer have been fulfilled or otherwise has decided to complete the Offer. Magle Group has reserved the right to extend the acceptance period for the Offer and to postpone the settlement date. Notice of any such extension or postponement will be announced by Magle Group by means of a press release.

Information about the Offer:

Information about the Offer is made available at:

<https://maglegroup.com/offer-erbjudande-amniotics>

For more information, please contact:

Justin Pierce, CEO

Email: justin.pierce@maglechemoswed.com

Telephone: +46 (0)70 593 58 21

For administrative questions regarding the Offer, please contact your bank or the nominee registered as holder of your shares.

The information in this announcement was submitted for publication by Magle Chemoswed Holding AB in accordance with the Takeover rules for certain trading platforms on 5 April 2024 at 08:30 a.m. (CEST).

Important information

This press release has been published in Swedish and English. In the event of any discrepancy in content between the two language versions, the Swedish version shall prevail.

The Offer is not being made, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, the United States or in any other jurisdiction where such offer would be prohibited by applicable law pursuant to legislation, restrictions and regulations in the relevant jurisdiction, by use of mail or any other communication means or instrumentality (including, without limitation, facsimile transmission, electronic mail, telex, telephone and the Internet) of interstate or foreign commerce, or of any facility of national securities exchange or other trading venue, of Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, the United States or in any other jurisdiction where such offer would be prohibited by applicable law pursuant to legislation, restrictions and regulations in the relevant jurisdiction, and the Offer cannot be accepted by any such means, instrumentality or facility of, in or from, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, the United States, or in any other jurisdiction where such offer would be prohibited by applicable law pursuant to legislation, restrictions and regulations in the relevant jurisdiction. Accordingly, this press release and any documentation relating to the Offer are not being and should not be sent, mailed or otherwise distributed or forwarded in or into Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or the United States or in any other jurisdiction where such offer would be prohibited by applicable law pursuant to legislation, restrictions and regulations in the relevant jurisdiction.

This press release is not being, and must not be, sent to shareholders with registered addresses in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or the United States. Banks, brokers, dealers and other nominees holding shares for persons in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, or the United States must not forward this press release or any other document received in connection with the Offer to such persons.

The Offer, the information and documents contained in this press release are not being made and have not been approved by an "authorised" person for the purposes of section 21 of the UK Financial Services and Markets Act 2000 (the "FSMA"). The communication of the information and documents contained in this press release is exempt from the restriction on financial promotions under section 21 of the FSMA on the basis that it is a communication by or on behalf of a body

corporate which relates to a transaction to acquire shares in a body corporate and the object of the transaction may reasonably be regarded as being the acquisition of day to day control of the affairs of that body corporate within article 62 (sale of a body corporate) of the FSMA (Financial Promotion) Order 2005.

Statements in this press release relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and the other benefits of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipates”, “intends”, “expects”, “believes”, or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Magle Group and Amniotics. Any such forward-looking statements speak only as of the date on which they are made and Magle Group has no obligation (and undertakes no such obligation) to update or revise any of them, whether as a result of new information, future events or otherwise, except for in accordance with applicable laws and regulations. The reader should, however, consult any additional disclosures that Magle Group or Amniotics have made or may make.

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and <https://maglegroup.com/> and www.maglepharmacept.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

[Magle Chemoswed Holding AB publishes offer document and announces updated timetable regarding the cash offer to the shareholders of Amniotics AB](#)